Transplants With Unlicensed Preserved Cord Blood | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01553461

Transplants With Unlicensed Preserved Cord Blood
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Cord blood transplants can treat cancers and other diseases in children and adults. The U.S. Food and Drug Administration (FDA) requires cord blood to be collected and stored under certain safety standards. However, most available cord blood units were collected before the FDA set these standards. These units may not meet FDA standards, but they do meet similar standards set and followed by the National Marrow Donor Program (NMDP). Cord blood units that do not meet the new FDA standards may be used for transplants only as part of a research study. Doctors want to allow people who need transplants to receive cord blood that meets NMDP standards but may not meet FDA standards.

Objectives:

- To allow selected cord blood units that do not meet current FDA standards to be used for transplant.

Eligibility:

- Individuals who need cord blood units for transplant, and who best match cord blood units that are not FDA-licensed.

Design:

  • Participants will provide consent to receive cord blood that meets NMDP standards but may not meet FDA standards.
  • Participants will remain on the study for observation for up to 1 year after transplant, or until they withdraw from the study for personal or medical reasons.
Status: 
Recruiting
Study Date: 
Wed, 02/01/2012 to Tue, 10/01/2030
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Procedure: Cord Blood Transplant